 control trial reduc daili dose zidovudin patient acquir immunodefici syndrom aid clinic trial group background dose zidovudin treatment patient advanc diseas human immunodefici viru type hiv mg dose effect substanti toxic method efficaci safeti dose trial subject first episod pneumocysti carinii pneumonia subject zidovudin dose mg hour standard-treat group dose mg hour week mg hour low-dos group result median length follow-up month month surviv rate percent standard-treat group percent low-dos group log-rank test month surviv rate percent standard-treat group percent low-dos group group percent subject opportunist infect length time infect similar group log-rank test t-lymphocyt count group serum level hiv antigen subject antigenemia hemoglobin level mmol liter liter subject standard-treat group low-dos group percent log-rank test neutrophil count liter subject standard-treat group low-dos group percent conclus reduc daili dose zidovudin studi effect standard dose toxic use four-week induct period high dose low-dos treatment sever anemia neutropenia common complic treatment zidovudin